Oncology and Haematologic Malignancies
Humanitas Mirasole S.p.A. supports clinical research in diffuse large B-cell lymphoma, high-grade B-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome, with additional work in recurrent metastatic nasopharyngeal carcinoma and hepatocellular carcinoma. The portfolio includes interest in disease settings that are refractory, relapsed, or resistant to prior treatment.
- Relapsed/refractory lymphoma after CAR T-cell therapy
- Acute myeloid leukemia and myelodysplastic syndrome
- Nasopharyngeal carcinoma
- Hepatocellular carcinoma
Research activity in this area reflects a strong focus on difficult-to-treat malignancies and post-treatment disease control.
Immune-Based Cancer Therapy
The sponsor is active in studies involving immunotherapy across solid tumours and blood cancers, including approaches that combine immune modulation with other anticancer treatment strategies. Areas of interest include checkpoint inhibition, monoclonal antibodies, and immune-directed treatment for resistant disease.
- Immune checkpoint inhibitor-related treatment strategies
- Monoclonal antibody-based cancer therapy
- Immune modulation in haematologic and solid tumours
These studies place emphasis on tumour response and safety in advanced cancer settings.
Cardiometabolic Disease
Clinical research also covers myocardial infarction and diabetes mellitus, with interest in preventing progression of coronary atherosclerosis after acute cardiac events. The sponsor’s cardiometabolic portfolio links vascular disease with metabolic risk management.
- Post-myocardial infarction cardiovascular care
- Diabetes mellitus and vascular disease
- Coronary atherosclerosis
This area includes research aimed at long-term cardiovascular stability in patients with metabolic comorbidity.
Rheumatology and Immune-Mediated Disease
The sponsor funds studies in rheumatoid arthritis, with attention to maintaining disease control in patients receiving TNF inhibitor therapy. This reflects an interest in chronic inflammatory disease management and optimisation of ongoing treatment.
- Rheumatoid arthritis
- TNF inhibitor-treated patients
- Disease control in chronic inflammation
The research focus supports care for patients requiring sustained management of immune-mediated joint disease.
Oral Premalignant Conditions
Another area of interest is oral disorders, particularly oral potentially malignant disorders at elevated risk of malignant transformation. The sponsor’s work in this field addresses early intervention in lesions with cancer risk.
- Oral potentially malignant disorders
- Malignant transformation risk
- Intralesional immunotherapy
This category highlights a preventive oncology focus within oral medicine.
